Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial

The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor   for Degradation in Breast Cancer Cells

(2009) X. Wu et al.   CANCER RESEARCH

Randomized Biomarker Trial of Anastrozole or Low-Dose Tamoxifen or Their Combination in Subjects with Breast Intraepithelial Neoplasia

(2009) B. Bonanni et al.   CLINICAL CANCER RESEARCH

Randomized Double-Blind 2 × 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in High-Risk Premenopausal Women

(2009) Andrea Decensi et al.   JOURNAL OF CLINICAL ONCOLOGY

Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations

(2009) Kyle J Ellis et al.   PHARMACOGENOMICS

CYP2C19*17 is associated with decreased breast cancer risk

(2008) Christina Justenhoven et al.   BREAST CANCER RESEARCH AND TREATMENT

Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis

(2008) R. S. Punglia et al.   JNCI-Journal of the National Cancer Institute